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Background/Aims: The exclusion of hepatitis B core an-
tibody (HBcAb)-positive donors from liver transplants (LTs) 
due to the risk of transmitting hepatitis B virus (HBV) does 
not appear to be practical in Korea, where hepatitis B is en-
demic. This study assessed the risk of de novo HBV infection 
in hepatitis B surface antigen (HBsAg)-negative LT recipients 
receiving a liver from HBcAb-positive donors. Methods: 
Of 341 adult living donor LTs conducted at our institution 
between March 2001 and September 2008, 176 donors 
(51.6%) were HBcAb-positive, and 26 HBcAb-positive grafts 
were transplanted to HBsAg-negative recipients. The median 
follow-up time after LT was 41.9 months. Results: Without 
anti-HBV prophylaxis, 2 out of 26 (7.7%) HBsAg-negative 
recipients who received grafts from HBcAb-positive donors 
developed de novo HBV infection 20 and 85 months after 
LT. These patients had been negative for all HBV serologic 
markers before transplantation. In both cases, there were 
no abnormalities in liver function tests upon diagnosis of 
de novo HBV infection. Conclusions: De novo HBV infection 
from HBcAb-positive donors after LT does not appear to be of 
great concern in terms of the number of cases in Korea be-
cause high risk patients who are HBV-negative comprise only 
a small proportion of the recipients. However, HBV-naïve LT 
recipients still carry the risk of developing de novo HBV infec-
tion as in non-HBV endemic areas. (Gut Liver 2011;5:363-366)
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INTRODUCTION
Owing to the discordance between the increment of potential 
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recipients for liver transplantation (LT) and a lack of available 
liver donors, there has been increased use of hepatitis B core 
antibody (HBcAb)-positive liver grafts.
1,2 However, liver grafts 
from HBcAb-positive donors carry the risk of transmitting 
hepatitis B virus (HBV) to hepatitis B surface antigen (HBsAg)-
negative recipients since occult HBV infection in the liver grafts 
can be reactivated in the recipient through the use of posttrans-
plant immunosuppression.
3-6
Because Korea is endemic for HBV and the rate of HBcAb 
positivity among liver donors reflects the prevalence of HBV in-
fection,
3 the prevalence of HBcAb positivity in Korea is greater 
than that of well-known low prevalence areas.
7 Accumulated 
experiences strongly recommend the administration of preven-
tive therapy for HBV- naïve recipients who receive grafts from 
HBcAb-positive donors, and anti-HBV prophylaxis is suggested 
to vaccinated recipients or the ones with isolated HBcAb.
8,9 
However, it is uncertain if it is suitable to apply these treat-
ments equally in HBV endemic areas. Thus, this study was con-
ducted to evaluate the risk of de novo HBV infection in HBsAg-
negative LT recipients who received grafts from HBcAb-positive 
donors in Korea, where the prevalence of HBcAb positivity is 
equally high in both donor and recipient groups. 
MATERIALS AND METHODS
From March 2001 to September 2008, 341 consecutive adult 
living donor liver transplantations (LDLT) were conducted at our 
institution. The median age of the 341 donors was 31 years, and 
176 donors (51.6%) were HBcAb-positive. Only 65 of the 341 
recipients were HBsAg-negative previous to LT. All recipients 
were followed-up for at least 15 months after LT. 
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HBV (HBcAb-negative, Hepatitis B surface antibody [HBsAb]-
negative), 11 were only HBsAb-positive, indicating that they 
had been previously vaccinated, 39 were positive for both HB-
cAb and HBsAb, indicating previous infection, and six were 
only positive for HBcAb. In the recipient population, the posi-
tive rate of HBcAb was 69.2% (45/65). The median age of the 
65 HBsAg-negative recipients was 51 years, and 26 of these 65 
recipients received HBcAb-positive grafts (Fig. 1). None of the 
HBsAg-negative recipients receiving liver grafts from HBcAb-
positive donors had received preventive therapy against de novo 
HBV infection at our center.
Instead of anti-HBV prophylaxis, recipients were routinely 
screened for serum HBsAg and HBV DNA at least every 3 
months or whenever graft dysfunction was suspected after LT. 
The median follow-up period after LT was 41.9 months (range, 
15 to 103 months). 
This study was conducted according to the current declara-
tion of Helsinki, and the protocol was approved by the Institu-
tional Ethics Committee at Seoul St. Mary’s Hospital in Korea. 
Baseline clinical and serologic markers were assessed. Continu-
ous variables were expressed as medians with ranges and were 
compared using the Mann-Whitney U-test. Categorical variables 
were expressed as the number of patients with percentage and 
were compared using the chi-square or the Fisher’s exact tests 
where appropriate. p-value less than 0.05 was considered to 
be significant. Software package SPSS version 14.0 (SPSS Inc., 
Fig. 1. Diagram of the study population. Of 341 adult living donor liver transplantations, 26 HBcAb-positive grafts were transplanted into HBsAg-
negative recipients. Without anti-HBV prophylaxis, 2 of the 26 (7.7%) recipients of positive grafts developed de novo HBV infection. 
LDLT, living donor liver transplantation; HBsAg, hepatitis B surface antigen; HBcAb, hepatitis B core antibody; HBsAb, hepatitis B surface anti-
body; HBV, Hepatitis B virus.
Table 1. Baseline Characteristics of 65 HBsAg-Negative Recipients
Characteristic
HBcAb (+) graft
(n=26)
HBcAb (-) graft
(n=39)
p-value
Recipient
  Age, yr 49.5 (24-63)   52 (20-63) 0.737
  Sex, n (%) 15 (57.5) 19 (48.7) 0.504
  HBcAb positivity, n (%) 18 (69.2) 27 (69.2) 1
  HBsAb positivity, n (%) 22 (84.6) 28 (71.8) 1.444
  Follow-up duration, mo 37.6 (18-88)  53.7 (15-103) 0.117
  Cause of transplantation
    (HAV/HCV/Alc/Autoimmune/Others), n (%)
5/4/8/3/6
(19.2/15.4/30.8/11.5/23.1)
4/8/10/7/10
(10.3/20.5/25.6/17.9/25.6)
0.8
Donor
  Age, yr 34.5 (18-54)   29 (18-49) 0.196
  Sex, n (%) 19 (73.1) 25 (64.1) 0.574
  HBsAb positivity, n (%) 19 (69.2) 29 (74.4) 0.651
Continuous variables are expressed as the median (range).
HBsAg, hepatitis B surface antigen; HBcAb, hepatitis B core antibody; HBsAb, hepatitis B surface antibody; HAV, hepatitis A virus; HCV, hepatitis 
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Chicago, IL, USA) was used for all statistical analyses.
RESULTS
The baseline characteristics of the 65 HBsAg-negative recipi-
ents are shown in Table 1. Without any prophylaxis, two out of 
the 26 (7.7%) HBsAg-negative recipients who received the graft 
from HBcAb-positive donors developed de novo HBV infection. 
Both recipients were naïve for all HBV serologic markers (i.e., 
HBsAg, HBsAb, and HBcAb) preoperatively. In one patient, Hb-
sAg turned out to be positive in serum at 20 months after LT. At 
the same time, HBsAb and HBeAg were positive, and HBV DNA 
level was 3.2×10
5 copies/mL. In the other patient, the positivity 
for HBsAg and HBeAg came out at 85 months after LT. HBsAb 
was negative and HBV DNA level was 1.0×10
9 copies/mL at that 
time. In both cases, de novo hepatitis B was detected by sero-
logical tests incidentally upon routine check-up without abnor-
mality in the liver function test. A liver biopsy was conducted in 
one of the two patients who developed de novo HBV infection. 
The results revealed a mild necro-inflammatory reaction, with a 
minimally positive stain for HBcAg but not for HBsAg in hepa-
tocytes. Both of these two recipients have been followed without 
administration of any treatment for HBV infection afterwards. 
About one year has passed since then, there were no significant 
changes of HBsAg, HBsAb, HBeAg status, and HBV DNA levels. 
Liver enzyme levels have been kept within normal range.
DISCUSSION
It has been reported that de novo HBV infection from HBcAb-
positive donors after LT occurs at a high rate especially in HBV-
naïve recipients without any prophylaxis. Thus there have been 
many attempts to minimize the risk for transmission of HBV to 
HBsAg-negative recipients using immunoprophylaxis regimens 
such as HBIG, lamivudine and vaccination. To date, accumu-
lated experiences have resulted in immunoprophylaxis being 
strongly recommended for HBV-naïve recipients receiving grafts 
from HBcAb-positive donors.
8-10 However, most of these studies 
were conducted in areas with low prevalence (3% to 4%) of HB-
cAb positivity. The liver donor population reflects the general 
population to some extent, and it is anticipated that the preva-
lence of HbcAb positivity in liver donors and the acquisition of 
HBV infection after LT would be high. As expected, the positive 
rate of HBcAb was 51.6% (176 out of 341 donors) in the LT do-
nor population and 69.2% (45 out of 65 recipients) in HBsAg-
negative recipients in our study, which are very high compared 
to those reported by Western countries with a low prevalence of 
HBV.
1,6,11,12
Conversely, development of de novo HBV was not as frequent 
as all that. De novo HBV was detected in two out of 26 (7.7%) 
HBsAg-negative LDLT recipients receiving HBcAb-positive liver 
grafts, and both of these were naïve for HBV preoperatively. 
Our results support those of previous studies that have found 
HBV-naïve recipients to be more prone to de novo HBV infec-
tion, but the total incidence of de novo HBV infection in the 
present study was lower than formerly reported.
8,9 This could 
be explained by the high prevalence of HBcAb positivity, and 
therefore small proportion of HBV naïve patients in the adult 
recipient population in an HBV endemic area like Korea. On the 
contrary, de novo HBV infection was reported at a relatively 
high rate in child LDLTs conducted using grafts from adult do-
nors in Korea.
13 A possible explanation is that HBV serologic 
markers are negative in most child LT recipients, while they 
are positive in half of adult donors.
13,14 Therefore, in the clini-
cal setting of child LDLTs in Korea, de novo HBV infection has 
been issued earlier, and anti-HBV prophylaxis has commonly 
been used. By contrast, de novo HBV infection in adult LDLTs 
has not drawn attention, and concensus on treatments for adult 
patients receiving liver allografts from HBcAb-positive donors 
has not been established until recently in Korea. Our long-term 
study clearly suggests that HBsAg-negative LT recipients from 
HBcAb-positive donors have a high risk of developing de novo 
HBV infection, particularly in clinical settings in which they 
are negative for all HBV serologic markers (i.e., HBsAg, HBcAb, 
HBsAb). Theoretically, among 65 HBsAg-negative recipients, 
only nine (13.8%) would be considered candidates for anti-HBV 
prophlylaxis when receiving liver grafts from HBcAb-positive 
donors.
As described above, there were no abnormalities in liver 
function tests upon diagnosis for de novo HBV infection, and 
one biopsy specimen showed mild necroinflammatory reaction 
with minimal staining for HBcAg. Although a biopsy was only 
conducted in one case, these findings imply that de novo HBV 
infection would not result in serious hepatitis if it were diag-
nosed by regular follow-up tests in HBsAg-negative recipients. 
Antiviral treatment for HBV was not prescribed to either patient. 
In the clinical setting of HBsAg-negative recipients receiving 
HBcAb-positive liver grafts, two strategic options may be taken 
into consideration: 1) anti-HBV prophylaxis in the recipient 
group at a high risk for developing de novo HBV infection, 2) 
routine follow-up for HBV markers and initiation of treatment 
when clinical hepatitis B is apparent. Only the latter has been 
applied at our institution since the development of drug resis-
tance in consequence of long-term use of nucleoside analogues 
for prophylaxis could be of concern, and effects on the graft 
have not been clearly demonstrated.
While the median follow-up time was 41.9 months with a 
maximum of 103 months, de novo HBV infection occurred at 
up to 85 months after LT in our study. This may have great 
clinical implications since at most 60 months was the longest 
period in earlier case reports.
2,15,16 Our results suggest that sur-
veillance should be conducted for a long period of time, and 
perhaps throughout the recipient’s lifetime.
In Korea, HBsAg-positive patients have mainly comprised 366  Gut and Liver, Vol. 5, No. 3, September 2011
adult LT recipient population. Therefore, reports about HBsAg-
negative recipients from HBcAb-positive donors has been lim-
ited. In our study, 19% (65/341) of adult LDLTs have not been 
attributed to HBV. Despite the limited cases, this study has the 
implication that the study population structure was different 
from that of Western series. About half of LT recipients in other 
studies conducted in areas with low prevalence of HBV con-
sisted of HBV-naïve recipients. But, only about 15% of LT re-
cipients were HBV-naïve in our series. To draw more conclusive 
results in different population, multicenter prospective studies 
will be needed. 
In conclusion, de novo HBV infection after LT using HbcAb-
positive grafts does not appear to be a significant concern in 
terms of the number of cases in Korea despite the high preva-
lence of HbcAb-positivity, since most of the recipients already 
had positive HBV serologic markers. However, prophylactic 
strategy should be taken into consideration since HBV-naïve LT 
recipients poses a particularly high-risk of developing de novo 
HBV infection after receiving allografts from HbcAb-positive 
donors as in areas with low prevalence of HBV infection.
CONFLICTS OF INTEREST
No potential conflict of interest relevant to this article was 
reported.
ACKNOWLEDGEMENTS
This work was funded by a grant (A050021, Liver Cirrhosis 
Clinical Research Center) of the Korea Health 21 Research and 
Development Project, Ministry of Health and Welfare, Republic 
of Korea.
REFERENCES
1. Wachs ME, Amend WJ, Ascher NL, et al. The risk of transmission 
of hepatitis B from HBsAg(-), HBcAb(+), HBIgM(-) organ donors. 
Transplantation 1995;59:230-234. 
2. Donataccio D, Roggen F, De Reyck C, Verbaandert C, Bodeus M, 
Lerut J. Use of anti-HBc positive allografts in adult liver trans-
plantation: toward a safer way to expand the donor pool. Transpl 
Int 2006;19:38-43. 
3. Prieto M, Gömez MD, Berenguer M, et al. De novo hepatitis B 
after liver transplantation from hepatitis B core antibody-positive 
donors in an area with high prevalence of anti-HBc positivity in 
the donor population. Liver Transpl 2001;7:51-58. 
4.  Rokuhara A, Tanaka E, Yagi S, et al. De novo infection of hepatitis 
B virus in patients with orthotopic liver transplantation: analysis 
by determining complete sequence of the genome. J Med Virol 
2000;62:471-478. 
5. Roche B, Samuel D, Gigou M, et al. De novo and apparent de 
novo hepatitis B virus infection after liver transplantation. J Hepa-
tol 1997;26:517-526.
6. Dickson RC, Everhart JE, Lake JR, et al. Transmission of hepatitis 
B by transplantation of livers from donors positive for antibody 
to hepatitis B core antigen. The National Institute of Diabetes and 
Digestive and Kidney Diseases Liver Transplantation Database. 
Gastroenterology 1997;113:1668-1674. 
7. Liu CJ, Chen DS, Chen PJ. Epidemiology of HBV infection in 
Asian blood donors: emphasis on occult HBV infection and the 
role of NAT. J Clin Virol 2006;36 Suppl 1:S33-S44. 
8. Avelino-Silva VI, D’Albuquerque LA, Bonazzi PR, et al. Liver 
transplant from Anti-HBc-positive, HBsAg-negative donor into 
HBsAg-negative recipient: is it safe? A systematic review of the 
literature. Clin Transplant 2010;24:735-746. 
9. Cholongitas E, Papatheodoridis GV, Burroughs AK. Liver grafts 
from anti-hepatitis B core positive donors: a systematic review. J 
Hepatol 2010;52:272-279. 
10.  Saab S, Waterman B, Chi AC, Tong MJ. Comparison of differ-
ent immunoprophylaxis regimens after liver transplantation with 
hepatitis B core antibody-positive donors: a systematic review. 
Liver Transpl 2010;16:300-307. 
11.  Dodson SF, Bonham CA, Geller DA, Cacciarelli TV, Rakela J, Fung 
JJ. Prevention of de novo hepatitis B infection in recipients of 
hepatic allografts from anti-HBc positive donors. Transplantation 
1999;68:1058-1061. 
12.  Douglas DD, Rakela J, Wright TL, Krom RA, Wiesner RH. The 
clinical course of transplantation-associated de novo hepatitis 
B infection in the liver transplant recipient. Liver Transpl Surg 
1997;3:105-111. 
13. Lee KW, Lee DS, Lee HH, et al. Prevention of de novo hepatitis B 
infection from HbcAb-positive donors in living donor liver trans-
plantation. Transplant Proc 2004;36:2311-2312. 
14.  Kwon CH, Suh KS, Yi NJ, et al. Long-term protection against hep-
atitis B in pediatric liver recipients can be achieved effectively with 
vaccination after transplantation. Pediatr Transplant 2006;10:479-
486. 
15.  Takemura N, Sugawara Y, Tamura S, Makuuchi M. Liver trans-
plantation using hepatitis B core antibody-positive grafts: review 
and university of Tokyo experience. Dig Dis Sci 2007;52:2472-
2477. 
16.  Uemoto S, Sugiyama K, Marusawa H, et al. Transmission of hepa-
titis B virus from hepatitis B core antibody-positive donors in liv-
ing related liver transplants. Transplantation 1998;65:494-499. 